Kyverna Therapeutics, Inc. (KYTX)
5.15
-0.01
(-0.19%)
USD |
NASDAQ |
Nov 04, 16:00
5.12
-0.03
(-0.58%)
After-Hours: 20:00
Kyverna Therapeutics Enterprise Value : 151.27M for Nov. 3, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 03, 2026 | 151.27M |
| November 02, 2026 | 154.97M |
| October 30, 2026 | 182.67M |
| October 29, 2026 | 193.76M |
| October 28, 2026 | 196.22M |
| October 27, 2026 | 180.21M |
| October 26, 2026 | 158.05M |
| October 23, 2026 | 165.43M |
| October 22, 2026 | 186.37M |
| October 21, 2026 | 193.14M |
| October 20, 2026 | 205.46M |
| October 19, 2026 | 192.53M |
| October 16, 2026 | 182.67M |
| October 15, 2026 | 201.15M |
| October 14, 2026 | 183.60M |
| October 13, 2026 | 188.83M |
| October 12, 2026 | 215.92M |
| October 09, 2026 | 227.00M |
| October 08, 2026 | 214.07M |
| October 07, 2026 | 213.46M |
| October 06, 2026 | 212.84M |
| October 05, 2026 | 222.69M |
| October 02, 2026 | 216.54M |
| October 01, 2026 | 235.01M |
| September 30, 2026 | 252.25M |
| Date | Value |
|---|---|
| September 29, 2026 | 254.71M |
| September 28, 2026 | 253.48M |
| September 25, 2026 | 252.86M |
| September 24, 2026 | 263.95M |
| September 23, 2026 | 268.87M |
| September 22, 2026 | 295.96M |
| September 21, 2026 | 271.95M |
| September 18, 2026 | 272.57M |
| September 17, 2026 | 267.03M |
| September 16, 2026 | 258.41M |
| September 15, 2026 | 262.10M |
| September 14, 2026 | 289.19M |
| September 11, 2026 | 280.57M |
| September 10, 2026 | 286.11M |
| September 09, 2026 | 303.97M |
| September 08, 2026 | 330.44M |
| September 04, 2026 | 341.53M |
| September 03, 2026 | 347.68M |
| September 02, 2026 | 364.00M |
| September 01, 2026 | 347.68M |
| August 31, 2026 | 355.38M |
| August 28, 2026 | 348.91M |
| August 27, 2026 | 365.54M |
| August 26, 2026 | 363.69M |
| August 25, 2026 | 377.85M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.177B |
| Oncolytics Biotech, Inc. | 44.94M |
| Sangamo Therapeutics, Inc. | 40.22M |
| Sarepta Therapeutics, Inc. | 2.216B |
| Anixa Biosciences, Inc. | 90.70M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -38.32M |
| Total Expenses (Quarterly) | 38.32M |
| EPS Diluted (Quarterly) | -0.6292 |
| Earnings Yield | -57.00% |
| Normalized Earnings Yield | -57.00 |